Stocks to Watch: Pamt, CXApp, Sangamo Therapeutics

Dow Jones

Apr 04

By Connor Hart

Pamt commenced a self-tender offer to purchase up to 435,000 shares. The company, which provides truckload and logistics services through its subsidiaries, said the shares account for about 2% of its outstanding common stock. It won't pay less than $14 a share or more than $17 a share, and it expects to pay for the shares largely using available cash and cash equivalents. Shares climb 25%, to $13.91, in after-hours trading.

CXApp posted what it called record annual revenue and said it expects significantly higher demand for its agentic artificial intelligence this year. The workplace-experience-solutions provider said it logged double-digit growth in recurring revenue in 2024 compared with the prior year, driven by higher subscription revenue. Looking forward, it will continue its focus of investing in agentic AI. Shares jump 59%, to $1.28, in post-market trading.

Sangamo Therapeutics entered a licensing agreement with Eli Lilly. Under the deal, the genomic-medicine company Sangamo said Lilly would receive rights to employ STAC-BBB, its proprietary capsid for up to five potential disease targets. Sangamo will receive $18 million as an upfront license fee, and is eligible to receive up to $1.4 billion in additional license fees, milestone payments, and tiered royalties. Shares rise 33%, to 83 cents, in after-hours trading.

Write to Connor Hart at connor.hart@wsj.com

(END) Dow Jones Newswires

April 03, 2025 19:37 ET (23:37 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

LOGIN / SIGN UP

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/news/2524248740"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2524248740\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2524248740?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-04-04 07:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2524248740","market":"fut","top_or_hot":-1,"title":"Stocks to Watch: Pamt, CXApp, Sangamo Therapeutics","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Pamt commenced a self-tender offer to purchase up to 435,000 shares. The company, which provides truckload and logistics services through its subsidiaries, said the shares account for about 2% of its outstanding common stock. It won't pay less than $14 a share or more than $17 a share, and it expects to pay for the shares largely using available cash and cash equivalents. Shares climb 25%, to $13.91, in after-hours trading. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/CXAI\">CXApp</a> posted what it called record annual revenue and said it expects significantly higher demand for its agentic artificial intelligence this year. The workplace-experience-solutions provider said it logged double-digit growth in recurring revenue in 2024 compared with the prior year, driven by higher subscription revenue. Looking forward, it will continue its focus of investing in agentic AI. Shares jump 59%, to $1.28, in post-market trading. \n</p>\n<p>\n  Sangamo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> entered a licensing agreement with Eli Lilly. Under the deal, the genomic-medicine company Sangamo said Lilly would receive rights to employ STAC-BBB, its proprietary capsid for up to five potential disease targets. Sangamo will receive $18 million as an upfront license fee, and is eligible to receive up to $1.4 billion in additional license fees, milestone payments, and tiered royalties. Shares rise 33%, to 83 cents, in after-hours trading. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 03, 2025 19:37 ET (23:37 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stocks to Watch: Pamt, CXApp, Sangamo Therapeutics</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStocks to Watch: Pamt, CXApp, Sangamo Therapeutics\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-04-04 07:37</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Connor Hart \n</p>\n<pre>\n \n</pre>\n<p>\n  Pamt commenced a self-tender offer to purchase up to 435,000 shares. The company, which provides truckload and logistics services through its subsidiaries, said the shares account for about 2% of its outstanding common stock. It won't pay less than $14 a share or more than $17 a share, and it expects to pay for the shares largely using available cash and cash equivalents. Shares climb 25%, to $13.91, in after-hours trading. \n</p>\n<p>\n  <a href=\"https://laohu8.com/S/CXAI\">CXApp</a> posted what it called record annual revenue and said it expects significantly higher demand for its agentic artificial intelligence this year. The workplace-experience-solutions provider said it logged double-digit growth in recurring revenue in 2024 compared with the prior year, driven by higher subscription revenue. Looking forward, it will continue its focus of investing in agentic AI. Shares jump 59%, to $1.28, in post-market trading. \n</p>\n<p>\n  Sangamo <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> entered a licensing agreement with Eli Lilly. Under the deal, the genomic-medicine company Sangamo said Lilly would receive rights to employ STAC-BBB, its proprietary capsid for up to five potential disease targets. Sangamo will receive $18 million as an upfront license fee, and is eligible to receive up to $1.4 billion in additional license fees, milestone payments, and tiered royalties. Shares rise 33%, to 83 cents, in after-hours trading. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Connor Hart at connor.hart@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  April 03, 2025 19:37 ET (23:37 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4134","symbol_name":"信息科技咨询与其它服务","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2524248740","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2524248740","pubTimestamp":1743723420,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Pamt commenced a self-tender offer to purchase up to 435,000 shares. The company, which provides truckload and logistics services through its subsidiaries, said the shares account for about 2% of its outstanding common stock. It won't pay less than $14 a share or more than $17 a share, and it expects to pay for the shares largely using available cash and cash equivalents. Shares climb 25%, to $13.91, in after-hours trading.CXApp posted what it called record annual revenue and said it expects significantly higher demand for its agentic artificial intelligence this year. The workplace-experience-solutions provider said it logged double-digit growth in recurring revenue in 2024 compared with the prior year, driven by higher subscription revenue. Looking forward, it will continue its focus of investing in agentic AI. Shares jump 59%, to $1.28, in post-market trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4134":"信息科技咨询与其它服务","LENZ":"Therapeutics","SGMO":"Sangamo Therapeutics Inc","CXAI":"CXApp","BK4232":"货物陆运","BK4139":"生物科技","BK4556":"基因编辑","BK4023":"应用软件","PAMT":"PAMT CORP"},"translate_title":"值得关注的股票：Pamt、CXApp、Sangamo Therapeutics","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CXAI":1,"LENZ":1,"PAMT":0.9,"SGMO":0.9},"content_text":"By Connor Hart \n\n\n \n\n\n  Pamt commenced a self-tender offer to purchase up to 435,000 shares. The company, which provides truckload and logistics services through its subsidiaries, said the shares account for about 2% of its outstanding common stock. It won't pay less than $14 a share or more than $17 a share, and it expects to pay for the shares largely using available cash and cash equivalents. Shares climb 25%, to $13.91, in after-hours trading. \n\n\nCXApp posted what it called record annual revenue and said it expects significantly higher demand for its agentic artificial intelligence this year. The workplace-experience-solutions provider said it logged double-digit growth in recurring revenue in 2024 compared with the prior year, driven by higher subscription revenue. Looking forward, it will continue its focus of investing in agentic AI. Shares jump 59%, to $1.28, in post-market trading. \n\n\n  Sangamo Therapeutics entered a licensing agreement with Eli Lilly. Under the deal, the genomic-medicine company Sangamo said Lilly would receive rights to employ STAC-BBB, its proprietary capsid for up to five potential disease targets. Sangamo will receive $18 million as an upfront license fee, and is eligible to receive up to $1.4 billion in additional license fees, milestone payments, and tiered royalties. Shares rise 33%, to 83 cents, in after-hours trading. \n\n\n \n\n\n  Write to Connor Hart at connor.hart@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  April 03, 2025 19:37 ET (23:37 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}